Cleveland Clinic spinout Juventas Therapeutics raises $13.5M for cardiovascular gene therapy
Juventas raises $13.5M for its gene therapy that helps repair damaged cardiovascular tissue with the body's own stem cells.
Regenerative medicine company begins enrollment in critical limb ischemia trial
Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients. The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is planning to enroll 48 patients and complete enrollment early next year, CEO Rahul Aras said. Juventas’ technology, called JVS-100, works by recruiting stem cells […]
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Takeda to invest in regenerative medicine startup Juventas’ next round
Takeda Pharmaceuticals is a strategic investor in regenerative medicine company Juventas Therapeutics’ upcoming series B round of funding. Juventas’ CEO Rahul Aras discussed the investment during a panel at a meeting of the Ohio Venture Association on Friday. “If you think venture capital due diligence is difficult …” Aras joked, “I think [Takeda] called my […]
Regenerative medicine startup to begin enrollment in phase 2 heart failure trial
Regenerative medicine startup Juventas Therapeutics is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter. The Cleveland-based company’s technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury. During the trial, Juventas […]
Regenerative medicine company encouraged by heart failure trial
Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart […]
Juventas’ stem cell therapy shows promise in phase 1 study
A phase 1 clinical trial has shown that Juventas Therapeutics‘ regenerative medicine therapy provides clinical benefit to heart failure patients. Phase 1 trials generally focus on safety, so the indication of clinical benefit is an encouraging sign for Cleveland-based Juventas. “We are excited to see strong signs of efficacy across multiple clinical parameters,” CEO Rahul […]
Health Benefit Consultants, Share Your Expert Insights in Our Survey
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
Regenerative medicine startup Juventas completes phase 1 heart failure trial
Cleveland Clinic spinoff Juventas Therapeutics has successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients. Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. In addition to heart failure patients, the company is investigating the treatment of patients suffering […]
Cleveland Clinic, JumpStart invest $500k in wound therapy startup
SironRX hopes to raise $2.5 million, which it would use to fund a Phase 2 clinical trial of its wound-healing technology.
Juventas Therapeutics to begin Phase 2 trial for critical limb ischemia
Regenerative medicine company Juventas Therapeutics Inc. has received regulatory approval to begin a Phase 2 clinical trial of critical limb ischemia patients.
Cleveland Clinic Innovations starts next decade with 33 companies
Updated 4:36 p.m. Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies. Perhaps most impressive, those companies — 33 in all — have attracted more than $340 million […]
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Juventas Therapeutics starts Phase 1 trial for heart failure
Clinical-stage regenerative medicine company Juventas Therapeutics Inc.–a Cleveland Clinic spin-off initially named AccelleRX–has started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure. In preclinical studies of heart failure in pigs, JVS-100, as the factor is known, significantly increased cardiac […]
Cleveland stem cell projects receive $10 million commercialization boost
The money will push two stem-cell technologies deeper into clinical trials and create Ohio's first Pluripotent Stem Cell Facility.